ATI RN
ATI Pharmacology Proctored Exam
1. A client has a new prescription for a Fentanyl transdermal patch. Which of the following instructions should the nurse include?
- A. Apply the patch to a non-hairy area.
- B. Change the patch every 72 hours.
- C. Avoid exposure to heat sources.
- D. Do not cut the patch to adjust the dosage.
Correct answer: C
Rationale: The correct instruction the nurse should include for a client using a Fentanyl transdermal patch is to avoid exposure to heat sources. Heat can increase the absorption of the medication, potentially causing an overdose. Instructing the client to avoid heat sources is crucial to ensure their safety and the effectiveness of the medication. Choices A, B, and D are incorrect because applying the patch to a non-hairy area, changing it every 72 hours, and not cutting the patch are general guidelines for using transdermal patches but do not specifically address the unique risks associated with Fentanyl patches.
2. When teaching a client about a new prescription for Celecoxib, which of the following information should the nurse include?
- A. Increases the risk for a myocardial infarction
- B. Decreases the risk of stroke
- C. Inhibits COX-1
- D. Increases platelet aggregation
Correct answer: A
Rationale: The nurse should educate the client that taking Celecoxib increases the risk of a myocardial infarction due to its suppression of vasodilation. Celecoxib belongs to the class of NSAIDs known to have cardiovascular risks, including an increased risk of heart attacks. Choice B is incorrect because Celecoxib does not decrease the risk of stroke. Choice C is incorrect because Celecoxib selectively inhibits COX-2 rather than COX-1. Choice D is incorrect because Celecoxib does not increase platelet aggregation; in fact, it inhibits platelet aggregation.
3. A client has a new prescription for Clozapine. Which of the following statements should the nurse include in the teaching?
- A. You should have a high-carbohydrate snack between meals and at bedtime.
- B. You are likely to develop hand tremors if you take this medication for a long period of time.
- C. You may experience temporary numbness of your mouth after each dose.
- D. You should have your white blood cell count monitored every week.
Correct answer: D
Rationale: Clozapine carries a risk for fatal agranulocytosis. To monitor for this serious adverse effect, it is crucial to check the client's white blood cell count weekly while they are on clozapine therapy.
4. Which of the following is not directly related to drug toxicity of Nitroglycerin?
- A. Headaches
- B. Tachycardia
- C. Dizziness
- D. Projectile vomiting
Correct answer: D
Rationale: Headaches, tachycardia, and dizziness are common side effects of nitroglycerin due to its vasodilatory properties. Projectile vomiting is not typically associated with nitroglycerin toxicity, making it the correct answer. Therefore, option D is the correct choice.
5. A healthcare provider is reviewing the health care record of a client who reports urinary incontinence and asks about a prescription for Oxybutynin. The provider should recognize that Oxybutynin is contraindicated in the presence of which of the following conditions?
- A. Bursitis
- B. Sinusitis
- C. Depression
- D. Glaucoma
Correct answer: D
Rationale: Oxybutynin is an anticholinergic medication that can increase intraocular pressure. It is contraindicated in clients with glaucoma, as it can worsen the condition. Glaucoma is a condition characterized by increased intraocular pressure, and using Oxybutynin can further elevate this pressure, potentially leading to serious complications such as vision impairment or damage to the optic nerve. Choices A, B, and C are incorrect as bursitis, sinusitis, and depression are not contraindications for Oxybutynin use. Therefore, the correct answer is D, Glaucoma.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access